EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Heterocyclic HIV Protease Inhibitors

Maria Funicello iD, Lucia Chiummiento iD, Alessandro Santarsiere iD, Francesco Poggio, Paolo Lupattelli iD

International Journal of Molecular Sciences · 16.09.2025 · 26 (18) · 9023

DOI: 10.3390/ijms26189023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.09.2025. Verfasst von Maria Funicello und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Applied Science, University of Basilicata, via dell'ateneo lucano 10, 85100 Potenza, Italy. Hauptthemen laut MEDLINE: HIV Protease Inhibitors, HIV Protease, Heterocyclic Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUR-Italy (Ministero dell’Università e della Ricerca)-PRIN 2022: Novel derivatives and nano-formulations of HIV-protease inhibitors for the treatment of colore…, Sapienza University of Rome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the first cases of AIDS, reported in 1980, this disease has become chronic over the years, and researchers have been trying to keep it under control. Despite the development and spread of mutate viruses, HIV protease remains an important pharmacological target. In the development of new HIV protease inhibitors, heterocyclic fragments have proven to be of great importance, owing to their rigid core structure, which may fit better into the enzyme’s hydrophobic pockets, and the presence of a heteroatom, which may increase the number of H-bonding interactions at the active site. According to the concept of targeting the protein backbone, different aromatic or non-aromatic heterocyclic moieties have yielded inhibitors with sufficient activity against mutant viruses. This paper provides an overview of HIV protease inhibitors developed over the last fifteen years, with a focus on the presence of heterocycles in their structure, either in the core or on the side chains, which are crucial for their activity. The rationale behind the design of these new inhibitors, as well as the key synthetic steps involved in their preparation, is also described.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Protease InhibitorsHIV ProteaseHeterocyclic CompoundsHumansHIV InfectionsDrug DesignStructure-Activity RelationshipHIV-1

Stichwörter der Autor:innen

AIDSHIV-1 protease inhibitorsbiological activityheterocyclessynthesis

Substanzen

HIV Protease InhibitorsHIV ProteaseHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Basic and Applied Science, University of Basilicata, via dell'ateneo lucano 10, 85100 Potenza, Italy.
  • Department of Chemistry, Sapienza University of Rome, p.le Aldo Moro 5, 00185 Roma, Italy.

ORCID-Profile: Maria Funicello, Lucia Chiummiento, Alessandro Santarsiere, Paolo Lupattelli

Förderung

  • MUR-Italy (Ministero dell’Università e della Ricerca)-PRIN 2022: Novel derivatives and nano-formulations of HIV-protease inhibitors for the treatment of colore…
  • Sapienza University of Rome

Zitieren

APA

Funicello, M., Chiummiento, L., Santarsiere, A., Poggio, F., & Lupattelli, P. (2025). Recent Advances in Heterocyclic HIV Protease Inhibitors. International Journal of Molecular Sciences, 26(18), 9023. https://doi.org/10.3390/ijms26189023

Vancouver

Funicello M, Chiummiento L, Santarsiere A, Poggio F, Lupattelli P. Recent Advances in Heterocyclic HIV Protease Inhibitors. International Journal of Molecular Sciences. 2025;26(18):9023. doi:10.3390/ijms26189023

BibTeX
@article{Funicello2025,
  author = {Funicello, Maria and Chiummiento, Lucia and Santarsiere, Alessandro and Poggio, Francesco and Lupattelli, Paolo},
  title = {Recent Advances in Heterocyclic HIV Protease Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {18},
  pages = {9023},
  doi = {10.3390/ijms26189023}
}
Kostenlos starten →